These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Specificity and efficacy of dendritic cell-based vaccination against tuberculosis with complex mycobacterial antigens in a mouse model. Rubakova E; Petrovskaya S; Pichugin A; Khlebnikov V; McMurray D; Kondratieva E; Baturina I; Kondratieva T; Apt A Tuberculosis (Edinb); 2007 Mar; 87(2):134-44. PubMed ID: 17011827 [TBL] [Abstract][Full Text] [Related]
3. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
4. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Wozniak TM; Ryan AA; Triccas JA; Britton WJ Infect Immun; 2006 Jan; 74(1):557-65. PubMed ID: 16369012 [TBL] [Abstract][Full Text] [Related]
5. Airway luminal T cells: a newcomer on the stage of TB vaccination strategies. Jeyanathan M; Heriazon A; Xing Z Trends Immunol; 2010 Jul; 31(7):247-52. PubMed ID: 20542470 [TBL] [Abstract][Full Text] [Related]
6. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
7. Restoration of innate immune activation accelerates Th1-cell priming and protection following pulmonary mycobacterial infection. Lai R; Jeyanathan M; Shaler CR; Damjanovic D; Khera A; Horvath C; Ashkar AA; Xing Z Eur J Immunol; 2014 May; 44(5):1375-86. PubMed ID: 24519467 [TBL] [Abstract][Full Text] [Related]
8. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Majlessi L; Simsova M; Jarvis Z; Brodin P; Rojas MJ; Bauche C; Nouzé C; Ladant D; Cole ST; Sebo P; Leclerc C Infect Immun; 2006 Apr; 74(4):2128-37. PubMed ID: 16552042 [TBL] [Abstract][Full Text] [Related]
9. Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection. Nambiar JK; Ryan AA; Kong CU; Britton WJ; Triccas JA Eur J Immunol; 2010 Jan; 40(1):153-61. PubMed ID: 19830735 [TBL] [Abstract][Full Text] [Related]
10. H2 complex controls CD4/CD8 ratio, recurrent responsiveness to repeated stimulations, and resistance to activation-induced apoptosis during T cell response to mycobacterial antigens. Pichugin AV; Petrovskaya SN; Apt AS J Leukoc Biol; 2006 Apr; 79(4):739-46. PubMed ID: 16415170 [TBL] [Abstract][Full Text] [Related]
11. Mycobacterium tuberculosis and dendritic cells: recognition, activation and functional implications. Sinha A; Salam N; Gupta S; Natarajan K Indian J Biochem Biophys; 2007 Oct; 44(5):279-88. PubMed ID: 18341202 [TBL] [Abstract][Full Text] [Related]
12. Partial and ineffective activation of V gamma 9V delta 2 T cells by Mycobacterium tuberculosis-infected dendritic cells. Meraviglia S; Caccamo N; Salerno A; Sireci G; Dieli F J Immunol; 2010 Aug; 185(3):1770-6. PubMed ID: 20592281 [TBL] [Abstract][Full Text] [Related]
13. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Xing Z; Lichty BD Tuberculosis (Edinb); 2006; 86(3-4):211-7. PubMed ID: 16504584 [TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guérin shares with virulent Mycobacterium tuberculosis the capacity to subvert monocyte differentiation into dendritic cell: implication for its efficacy as a vaccine preventing tuberculosis. Gagliardi MC; Teloni R; Mariotti S; Iona E; Pardini M; Fattorini L; Orefici G; Nisini R Vaccine; 2004 Sep; 22(29-30):3848-57. PubMed ID: 15364431 [TBL] [Abstract][Full Text] [Related]
15. Unique functions of splenic CD8alpha+ dendritic cells during infection with intracellular pathogens. Neuenhahn M; Busch DH Immunol Lett; 2007 Dec; 114(2):66-72. PubMed ID: 17964665 [TBL] [Abstract][Full Text] [Related]
16. Regulation of immune responses to Mycobacterium tuberculosis secretory antigens by dendritic cells. Latchumanan VK; Balkhi MY; Sinha A; Singh B; Sharma P; Natarajan K Tuberculosis (Edinb); 2005; 85(5-6):377-83. PubMed ID: 16246624 [TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
20. Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts. Malowany JI; McCormick S; Santosuosso M; Zhang X; Aoki N; Ngai P; Wang J; Leitch J; Bramson J; Wan Y; Xing Z Mol Ther; 2006 Apr; 13(4):766-75. PubMed ID: 16343993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]